Connect
MJA
MJA

An audit of the use of ondansetron in general medical patients

Penelope J Cotton and Samer Q Noaman
Med J Aust 2013; 199 (11): 748-750. || doi: 10.5694/mja13.10815
Published online: 16 December 2013

To the Editor: Ondansetron is a 5-HT3 receptor antagonist and an effective antiemetic in the treatment of acute chemotherapy- or radiotherapy-induced nausea and vomiting1 and postoperative nausea and vomiting.2 However, there is no evidence to support the superiority of ondansetron in the empirical management of undifferentiated nausea and vomiting,1 although this appears to have become common practice. Trials comparing ondansetron and other antiemetics (such as metoclopramide or promethazine) in the management of undifferentiated nausea have failed to show a significant difference in efficacy.3,4 Clinical guidelines for managing nausea and vomiting have been shown to increase compliance with consensus guidelines and reduce costs to health services associated with antiemetic prescribing.5

  • Penelope J Cotton
  • Samer Q Noaman

  • Ballarat Health Services, Ballarat, VIC.

Correspondence: penine@gmail.com

Acknowledgements: 

We would like to acknowledge the support of Ballarat Health Services in completing this audit, including the health information services staff for assistance in data extraction, and Kate Hamilton, Director of Oncology, for her guidance and support.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.